Cargando…

Universal theranostic CRISPR/Cas13a RNA-editing system for glioma

Background: The CRISPR/Cas13a system offers the advantages of rapidity, precision, high sensitivity, and programmability as a molecular diagnostic tool for critical illnesses. One of the salient features of CRISPR/Cas13a-based bioassays is its ability to recognize and cleave the target RNA specifica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Ye, Wang, Yunfei, Zhou, Junhu, Wang, Jianhao, Zhan, Qi, Wang, Qixue, Yang, Eryan, Jin, Weili, Tong, Fei, Zhao, Jixing, Hong, Biao, Liu, Junrui, Kang, Chunsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614676/ https://www.ncbi.nlm.nih.gov/pubmed/37908718 http://dx.doi.org/10.7150/thno.84429

Ejemplares similares

The CRISPR‐Cas13a Gene‐Editing System Induces Collateral Cleavage of RNA in Glioma Cells
por: Wang, Qixue, et al.
Publicado: (2019)

Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein
por: Wang, Lin, et al.
Publicado: (2021)

Collateral Effects: The CRISPR‐Cas13a Gene‐Editing System Induces Collateral Cleavage of RNA in Glioma Cells (Adv. Sci. 20/2019)
por: Wang, Qixue, et al.
Publicado: (2019)

Neuronal STAT3/HIF-1α/PTRF axis-mediated bioenergetic disturbance exacerbates cerebral ischemia-reperfusion injury via PLA2G4A
por: Jin, Weili, et al.
Publicado: (2022)

PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma
por: Yang, Eryan, et al.
Publicado: (2022)

Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance
por: Zhou, Junhu, et al.
Publicado: (2023)

Commentary: RNA editing with CRISPR-Cas13
por: Matsoukas, Ianis G.
Publicado: (2018)

Homotrimer cavin1 interacts with caveolin1 to facilitate tumor growth and activate microglia through extracellular vesicles in glioma
por: Wang, Lin, et al.
Publicado: (2020)

Crispr Library Screening: Genome‐Wide CRISPR‐Cas9 Screening Identifies NF‐κB/E2F6 Responsible for EGFRvIII‐Associated Temozolomide Resistance in Glioblastoma (Adv. Sci. 17/2019)
por: Huang, Kai, et al.
Publicado: (2019)

Expert opinion on translational research for advanced glioblastoma treatment
por: Cui, Xiaoteng, et al.
Publicado: (2023)

PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma
por: Yi, Kaikai, et al.
Publicado: (2022)

Genome‐Wide CRISPR‐Cas9 Screening Identifies NF‐κB/E2F6 Responsible for EGFRvIII‐Associated Temozolomide Resistance in Glioblastoma
por: Huang, Kai, et al.
Publicado: (2019)

Progresses, Challenges, and Prospects of CRISPR/Cas9 Gene-Editing in Glioma Studies
por: Kang, Xianhui, et al.
Publicado: (2023)

Applications of CRISPR/Cas13-Based RNA Editing in Plants
por: Kavuri, Naga Rajitha, et al.
Publicado: (2022)

HOTAIR Up-Regulation Activates NF-κB to Induce Immunoescape in Gliomas
por: Wang, Yunfei, et al.
Publicado: (2021)

Engineered circular guide RNAs boost CRISPR/Cas12a- and CRISPR/Cas13d-based DNA and RNA editing
por: Zhang, Xin, et al.
Publicado: (2023)

Early administration of MPC-n(IVIg) selectively accumulates in ischemic areas to protect inflammation-induced brain damage from ischemic stroke
por: Jin, Weili, et al.
Publicado: (2021)

Single-cell RNA-seq reveals RAD51AP1 as a potent mediator of EGFRvIII in human glioblastomas
por: Wang, Qixue, et al.
Publicado: (2019)

Insights Gained from RNA Editing Targeted by the CRISPR-Cas13 Family
por: Liu, Li, et al.
Publicado: (2022)

Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma
por: Cui, Xiaoteng, et al.
Publicado: (2023)

Single-Cell Transcriptomics of Glioblastoma Reveals a Unique Tumor Microenvironment and Potential Immunotherapeutic Target Against Tumor-Associated Macrophage
por: Cui, Xiaoteng, et al.
Publicado: (2021)

Enhancing Targeted Genomic DNA Editing in Chicken Cells Using the CRISPR/Cas9 System
por: Wang, Ling, et al.
Publicado: (2017)

An Update of Nucleic Acids Aptamers Theranostic Integration with CRISPR/Cas Technology
por: Roueinfar, Mina, et al.
Publicado: (2022)

CRISPR-Cas9-Based Genome Editing and Cytidine Base Editing in Acinetobacter baumannii
por: Wang, Yu, et al.
Publicado: (2020)

Next-Generation Sequencing and CRISPR/Cas13 Editing in Viroid Research and Molecular Diagnostics
por: Hadidi, Ahmed
Publicado: (2019)

Broad-spectrum CRISPR-Cas13a enables efficient phage genome editing
por: Adler, Benjamin A., et al.
Publicado: (2022)

CRISPR-Cas9 DNA Base-Editing and Prime-Editing
por: Kantor, Ariel, et al.
Publicado: (2020)

Implementation of the CRISPR-Cas13a system in fission yeast and its repurposing for precise RNA editing
por: Jing, Xinyun, et al.
Publicado: (2018)

FUNDC1-dependent mitophagy induced by tPA protects neurons against cerebral ischemia-reperfusion injury
por: Cai, Ying, et al.
Publicado: (2020)

Genome Editing in Bacteria: CRISPR-Cas and Beyond
por: Arroyo-Olarte, Ruben D., et al.
Publicado: (2021)

CRISPR/Cas9 or prime editing? – It depends on…
por: Schenke, Dirk
Publicado: (2020)

CRISPR/Cas9-mediated genome editing in nonhuman primates
por: Kang, Yu, et al.
Publicado: (2019)

Application of CRISPR/Cas9 Nuclease in Amphioxus Genome Editing
por: Su, Liuru, et al.
Publicado: (2020)

Editorial: Innovative theranostic approaches towards neuro-immunology in gliomas
por: Cui, Xiaoteng, et al.
Publicado: (2023)

HOXA13 is a potential GBM diagnostic marker and promotes glioma invasion by activating the Wnt and TGF-β pathways
por: Duan, Ran, et al.
Publicado: (2015)

Tissue plasminogen activator disrupts the blood-brain barrier through increasing the inflammatory response mediated by pericytes after cerebral ischemia
por: Yang, Eryan, et al.
Publicado: (2019)

An efficient sorghum protoplast assay for transient gene expression and gene editing by CRISPR/Cas9
por: Meng, Ruirui, et al.
Publicado: (2020)

Methods for in vitro CRISPR/CasRx-Mediated RNA Editing
por: Chuang, Yu-Fan, et al.
Publicado: (2021)

HDAC inhibitors improve CRISPR-Cas9 mediated prime editing and base editing
por: Liu, Nan, et al.
Publicado: (2022)

HDAC inhibitors improve CRISPR-Cas9 mediated prime editing and base editing
por: Liu, Nan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pdmn8fb3u8e16kh5anddu41inn